Abstract | PURPOSE: EXPERIMENTAL DESIGN: A potent and specific small-molecule inhibitor of the catalytic activity of TP, 6-(2-aminoethyl)amino-5-chlorouracil (AEAC), was tested for antiangiogenic and antitumor activity in human cancer xenografts in vivo. RESULTS: CONCLUSION: These studies show antitumor activity for a drug targeting TP and suggest that inhibitors of TP could be used to augment the clinical efficacy of drugs targeting the VEGF pathway.
|
Authors | Haiyan Lu, Robert S Klein, Edward L Schwartz |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 15
Issue 16
Pg. 5136-44
(Aug 15 2009)
ISSN: 1557-3265 [Electronic] United States |
PMID | 19671868
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- 6-(2-aminoethyl)amino-5-chlorouracil
- Angiogenesis Inhibitors
- Enzyme Inhibitors
- Uracil
- Thymidine Phosphorylase
- Receptors, Vascular Endothelial Growth Factor
|
Topics |
- Administration, Oral
- Angiogenesis Inhibitors
(administration & dosage)
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cell Proliferation
(drug effects)
- Cells, Cultured
- Enzyme Inhibitors
(administration & dosage)
- Female
- Humans
- Mice
- Mice, Nude
- Models, Biological
- Neoplasms
(drug therapy, metabolism, pathology)
- Receptors, Vascular Endothelial Growth Factor
(administration & dosage, antagonists & inhibitors)
- Thymidine Phosphorylase
(antagonists & inhibitors)
- Tumor Burden
(drug effects)
- Uracil
(administration & dosage, analogs & derivatives)
- Xenograft Model Antitumor Assays
|